+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture), By End-use (Hospitals, POCT, Laboratories), By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • February 2024
  • Region: Global
  • Grand View Research
  • ID: 3934195
Description Jump to:
The global influenza diagnostics market size is expected to reach USD 2.41 billion by 2030, registering a CAGR of 5.78% from 2024 to 2030. The increasing surveillance of the infection and the rising prevalence of chronic diseases around the world are contributing to the demand for influenza diagnostics. For instance, in September 2022, National Influenza Centres and other laboratories from 102 countries tested over 112,017 specimens between 22 August 2022 to 04 September 2022. Out of those, 3,879 tested positive for influenza viruses.

The increasing involvement of international organizations and regulations, such as WHO and the U.S. Department of Health & Human Services to control the spread of infection. The organizations are indulging in comprehensive research and development of a vaccine for influenza. It has been observed that various companies such as VIDRL, Seqirus, and CDC are developing cell culture-based vaccines. Thus, this strategic initiative is likely to have a positive impact on the market through increasing demand for cell culture technology.

For instance, in September 2022, WHO used a certified cell line including NIID-MDCK for isolating the human influenza virus. The organization also performed genetic and antigenic analysis on the cell culture-based candidate vaccine viruses. The vaccine candidates have passed two-way virus neutralization tests or hemagglutination inhibition against the cell culture prototype viruses and match the recommendation by WHO. It is anticipated that cell-culture-derived vaccine candidates will be available for development and production in 2023.

During the COVID-19 pandemic, the surveillance to monitor and detect the influenza virus drastically decreased. Similarly, the trend was witnessed in flu-related hospitalization cases between October to April. For instance, from October 2019 to April 2020, approximately 19,299 cases of hospitalization were reported in the U.S. While in the same months in 2020-21, only 232 cases were reported, hence, approximately 98% fall in the cases during the peak of COVID-19. However, WHO recommended countries be ready for the co-circulation of COVID-19 and influenza viruses. This encourages the regional regulations to integrate the surveillance program and step-up vaccination campaigns for flu.

The growing availability of point-of-care testing (POCT) in the area of rapid diagnostics of infectious diseases including flu, is expected to increase the demand for influenza diagnostics in developing countries. For instance, a study was conducted in October 2022, to assess the POCT scope for infectious diseases in European countries. As per the study, under surveillance, POCT is widely used for infectious diseases with significant incidence rates, such as HIV and flu.

Moreover, at the global level, flu activity is considerably low. As per the September 2022 report by WHO, the South African region has witnessed a significant rise in flu activity in the past few weeks, and majorly with influenza B viruses were reported. However, in regions such as Central Asia and Northern Africa, no detection of flu was reported. Decreasing incidence rates is anticipated to impact the growth of the market through low product development by companies.

Influenza Diagnostics Market Report Highlights

  • By test type, Rapid influenza diagnostics tests (RIDTs) segment led the market and accounted for 30.88% of the global revenue in 2023 and is expected to exhibit the fastest CAGR over the forecast period. Owing to the increasing strategic initiatives such as product development and expanding the scope of usage to public events by the companies, hence, driving the market growth
  • By end-user, the hospitals accounted for largest market revenue share in 2023. This is attributed to the growing presence of underlying medical conditions such as asthma and other chronic health conditions, which increases the risk of flu complications
  • North America dominated the market and accounted for a 32.69% share in 2023 of the overall market share. Owing to the increasing accessibility of data on the influenza burden to the companies, and rising surveillance testing in the region.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test Type
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type outlook
2.2.2. End Use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Influenza Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rising geriatric population
3.2.1.2. Increasing prevalence of diseases
3.2.1.3. Government initiatives to counter influenza
3.2.1.4. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Product safety and high development cost
3.3. Influenza Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
Chapter 4. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis
4.1. Test Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Influenza Diagnostics Market by Test Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. RIDT
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. RT-PCR
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Cell Culture
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Influenza Diagnostics Market: End-Use Estimates & Trend Analysis
5.1. End-Use Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Influenza Diagnostics Market by End Use Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Hospitals
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
5.4.2. POCT
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Laboratories
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Influenza Diagnostics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2023 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. North America
6.5.1. U.S.
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Canada
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Europe
6.6.1. UK
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. Germany
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. France
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Italy
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. Spain
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Norway
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.6.7. Sweden
6.6.7.1. Key country dynamics
6.6.7.2. Regulatory framework/ reimbursement structure
6.6.7.3. Competitive scenario
6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.6.8. Denmark
6.6.8.1. Key country dynamics
6.6.8.2. Regulatory framework/ reimbursement structure
6.6.8.3. Competitive scenario
6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Asia Pacific
6.7.1. Japan
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. China
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.7.3. India
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework/ reimbursement structure
6.7.3.3. Competitive scenario
6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.7.4. Australia
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework/ reimbursement structure
6.7.4.3. Competitive scenario
6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.7.5. South Korea
6.7.5.1. Key country dynamics
6.7.5.2. Regulatory framework/ reimbursement structure
6.7.5.3. Competitive scenario
6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.7.6. Thailand
6.7.6.1. Key country dynamics
6.7.6.2. Regulatory framework/ reimbursement structure
6.7.6.3. Competitive scenario
6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Mexico
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. Argentina
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework/ reimbursement structure
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework/ reimbursement structure
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework/ reimbursement structure
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework/ reimbursement structure
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2023
7.3.4. 3M Company
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Abbott Laboratories
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Becton, Dickinson and Company
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Meridian Bioscience, Inc.
7.3.7.1. Company overview
7.3.7.2. Financial performance
7.3.7.3. Product benchmarking
7.3.7.4. Strategic initiatives
7.3.8. Quidel Corporation.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. F. Hoffmann-La Roche Ltd.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. SA Scientific Ltd
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. SEKISUI Diagnostics
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. Thermo Fisher Scientific, Inc.
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Hologic, Inc.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
Table 3 North America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 North America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 5 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 6 U.S. influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 7 Canada influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 8 Canada influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 9 Europe influenza diagnostics market, by region, 2018 - 2030 (USD Million)
Table 10 Europe influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 11 Europe influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 12 Germany influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 13 Germany influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 14 UK influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 15 UK influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 16 France influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 17 France influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 18 Italy influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 19 Italy influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 20 Spain influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 21 Spain influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 22 Denmark influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 23 Denmark influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 24 Sweden influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 25 Sweden influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 26 Norway influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 27 Norway influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 28 Asia Pacific influenza diagnostics market, by region, 2018 - 2030 (USD Million)
Table 29 Asia Pacific influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 30 Asia Pacific influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 31 China influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 32 China influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 33 Japan influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 34 Japan influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 35 India influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 36 India influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 37 South Korea influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 38 South Korea influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 39 Australia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 40 Australia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 41 Thailand influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 42 Thailand influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 43 Latin America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
Table 44 Latin America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 45 Latin America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 46 Brazil influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 47 Brazil influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 48 Mexico influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 49 Mexico influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 50 Argentina influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 51 Argentina influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 52 MEA influenza diagnostics market, by region, 2018 - 2030 (USD Million)
Table 53 MEA influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 54 MEA influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 55 South Africa influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 56 South Africa influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 59 UAE influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 60 UAE influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
Table 61 Kuwait influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 62 Kuwait influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Influenza diagnostics market: market outlook
Fig. 14 Influenza diagnostics competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Influenza diagnostics market driver impact
Fig. 20 Influenza diagnostics market restraint impact
Fig. 21 Influenza diagnostics market strategic initiatives analysis
Fig. 22 Influenza diagnostics market: Test Type movement analysis
Fig. 23 Influenza diagnostics market: Test Type outlook and key takeaways
Fig. 24 RIDT market estimates and forecast, 2018 - 2030
Fig. 25 RT-PCR estimates and forecast, 2018 - 2030
Fig. 26 Cell Culture market estimates and forecast, 2018 - 2030
Fig. 27 Others estimates and forecast, 2018 - 2030
Fig. 28 Influenza diagnostics Market: End Use movement Analysis
Fig. 29 Influenza diagnostics market: End use movement analysis
Fig. 30 Influenza diagnostics market: End use outlook and key takeaways
Fig. 31 Hospitals market estimates and forecasts, 2018 - 2030
Fig. 32 POCT market estimates and forecasts,2018 - 2030
Fig. 33 Laboratories market estimates and forecasts,2018 - 2030
Fig. 34 Global influenza diagnostics market: Regional movement analysis
Fig. 35 Global influenza diagnostics market: Regional outlook and key takeaways
Fig. 36 Global influenza diagnostics market share and leading players
Fig. 37 North America market share and leading players
Fig. 38 Europe market share and leading players
Fig. 39 Asia Pacific market share and leading players
Fig. 40 Latin America market share and leading players
Fig. 41 Middle East & Africa market share and leading players
Fig. 42 North America, by country
Fig. 43 North America market estimates and forecasts, 2018 - 2030
Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
Fig. 45 Canada market estimates and forecasts, 2018 - 2030
Fig. 46 Europe market estimates and forecasts, 2018 - 2030
Fig. 47 UK market estimates and forecasts, 2018 - 2030
Fig. 48 Germany market estimates and forecasts, 2018 - 2030
Fig. 49 France market estimates and forecasts, 2018 - 2030
Fig. 50 Italy market estimates and forecasts, 2018 - 2030
Fig. 51 Spain market estimates and forecasts, 2018 - 2030
Fig. 52 Denmark market estimates and forecasts, 2018 - 2030
Fig. 53 Sweden market estimates and forecasts, 2018 - 2030
Fig. 54 Norway market estimates and forecasts, 2018 - 2030
Fig. 55 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 56 China market estimates and forecasts, 2018 - 2030
Fig. 57 Japan market estimates and forecasts, 2018 - 2030
Fig. 58 India market estimates and forecasts, 2018 - 2030
Fig. 59 Thailand market estimates and forecasts, 2018 - 2030
Fig. 60 South Korea market estimates and forecasts, 2018 - 2030
Fig. 61 Australia market estimates and forecasts, 2018 - 2030
Fig. 62 Latin America market estimates and forecasts, 2018 - 2030
Fig. 63 Brazil market estimates and forecasts, 2018 - 2030
Fig. 64 Mexico market estimates and forecasts, 2018 - 2030
Fig. 65 Argentina market estimates and forecasts, 2018 - 2030
Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 67 South Africa market estimates and forecasts, 2018 - 2030
Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 69 UAE market estimates and forecasts, 2018 - 2030
Fig. 70 Kuwait market estimates and forecasts, 2018 - 2030
Fig. 71 Market share of key market players- influenza diagnostics market

Companies Mentioned

  • 3M Company
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Meridian Bioscience, Inc.
  • Quidel Corporation.
  • F. Hoffmann-La Roche Ltd.
  • SA Scientific Ltd
  • SEKISUI Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Hologic, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedFebruary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 1.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.41 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Influenza Diagnostics Market by Test Type (Cell Culture, Rapid Influenza Diagnostic Tests, Reverse Transcription-Polymerase Chain Reaction), End-User (Hospitals, Laboratories, Point-Of-Care Testing) - Forecast 2024-2030 - Product Image

Global Influenza Diagnostics Market by Test Type (Cell Culture, Rapid Influenza Diagnostic Tests, Reverse Transcription-Polymerase Chain Reaction), End-User (Hospitals, Laboratories, Point-Of-Care Testing) - Forecast 2024-2030

  • Report
  • 182 Pages
  • Global
From
Influenza Diagnostics - Global Strategic Business Report - Product Image

Influenza Diagnostics - Global Strategic Business Report

  • Report
  • 171 Pages
  • Global
From
Influenza Diagnostics Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030 - Product Image

Influenza Diagnostics Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030

  • Report
  • 146 Pages
  • Global
From
Influenza Diagnostic Global Market Report 2024 - Product Image

Influenza Diagnostic Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Global Influenza Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Global Influenza Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 118 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.